Home›Drug Pipeline› Network meta-analysis compares prophylactic anticoagulants for central venous catheter-related thrombosis in cancer patients
Network meta-analysis compares prophylactic anticoagulants for central venous catheter-related thrombosis in cancer patientsCancer Patients May Avoid Clots With Safer Blood Thinner
Frontiers in MedicinePublished April 19, 2026DOI ↗Editorial oversight: Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Note apixaban reduces CRT incidence versus no prophylaxis, but VKA increases bleeding risk; long-term safety data needed.
This Bayesian network meta-analysis evaluates prophylactic anticoagulation strategies for central venous catheter-related thrombosis in cancer patients. The review included 19 clinical studies comparing apixaban, vitamin K antagonists, rivaroxaban, and low-molecular-weight heparin against no prophylaxis. The primary outcome focused on central venous catheter-related thrombosis incidence, with secondary outcomes assessing bleeding risk, major bleeding, all-cause mortality, and adverse events.
Regarding thrombosis prevention, apixaban reduced central venous catheter-related thrombosis incidence compared with no prophylaxis, yielding an OR 0.31 with a 95% CI 0.17–0.54. Vitamin K antagonists, rivaroxaban, and low-molecular-weight heparin also showed significant reductions compared with no prophylaxis, though specific effect sizes were not reported for these comparisons. Conversely, vitamin K antagonists were associated with a higher bleeding risk than apixaban and no prophylaxis, with an OR 2.29 and a 95% CI 1.08–4.98. No significant differences were found among other treatments for major bleeding, all-cause mortality, or adverse events.
The authors note that long-term safety data from large-scale, multicenter trials are still needed to fully establish the safety profile of these interventions. Practice relevance suggests findings support the favorable effect of direct oral anticoagulants on central venous catheter-related thrombosis prevention. However, the search date extended up to 28 May 2025, and a bibliometric analysis included 680 publications, indicating a broad evidence base. Clinicians should interpret these results within the context of the included studies and acknowledge the limitations regarding long-term safety data.
Why Clots Are A Major Risk
Central venous catheters are tubes used to deliver medicine directly into the bloodstream. They are common for people with cancer. But these tubes can sometimes trigger clots. This condition is called catheter-related thrombosis. It can block blood flow and cause serious harm. Studies show it increases the risk of death. It also leads to more hospital visits.
The Shift In Treatment Plans
Doctors used to rely on older blood thinners like warfarin. These drugs work, but they require frequent blood tests. They also carry a higher risk of bleeding. Newer options exist, but evidence was unclear. Researchers wanted to know which drug works best. They needed to compare safety and effectiveness.
How Blood Thinners Work Simply
Think of blood clotting like a traffic jam. Platelets pile up to stop bleeding. Sometimes they pile up too much and block the road. Blood thinners act like traffic controllers. They keep the flow moving smoothly without causing accidents. This balance is hard to find. Too much thinning causes bleeding. Too little causes clots.
Scientists looked at 680 research papers from around the world. They focused on nineteen clinical studies involving cancer patients. They compared different medicines used to prevent these clots. The goal was to find the safest and most effective choice. This analysis covered data from fifty-two countries. It looked at research published over twenty-five years.
The Surprising Winner Emerges
The results pointed to a drug called apixaban. It reduced the chance of clots significantly compared to doing nothing. It also performed better than older options like warfarin. Patients taking warfarin had a higher risk of bleeding. Apixaban kept the clot risk low without the extra danger. Other drugs like rivaroxaban also showed promise.
This does not mean this treatment is available yet.
What Experts Say About Safety
Medical leaders see this as a positive step forward. It suggests newer drugs might be safer for patients. However, they warn that more time is needed. We need to see what happens over many years. The study highlights the need for large-scale trials.
If you have a central line, talk to your doctor. Do not change your medication on your own. This study helps guide future choices. But your care team knows your specific health history best. They will weigh the risks for your body.
The Limits Of This Research
No study is perfect. This analysis combined many different trials. Some data might not be fully comparable. We still need large-scale trials to confirm long-term safety. The findings are promising but not final.
Researchers will keep watching how these drugs perform. Approval processes take time to ensure safety. Patients can hope for better options in the future. Science moves slowly, but it moves forward.
BackgroundCatheter-related thrombosis (CRT) is a common complication following central venous catheter (CVC) placement in patients with cancer, increasing mortality and adverse outcomes. However, robust evidence on optimal prophylactic anticoagulation strategies remains limited.MethodsA bibliometric analysis was performed on English-language publications on CVC-associated thrombosis prevention in cancer patients indexed in the Web of Science (2000–2025). Descriptive analyses were conducted using the Bibliometrix package in R, with visualizations generated by VOSviewer and CiteSpace. For the network meta-analysis, clinical studies on prophylactic anticoagulation for CRT in cancer patients were systematically searched (up to 28 May 2025), and a Bayesian network meta-analysis was performed using R packages netmeta and gemtc.ResultsA total of 680 publications from 52 countries were identified. The United States led in both publication output and citations, and research focus shifted from warfarin and low-molecular-weight heparin (LMWH) toward direct oral anticoagulants (DOACs). Nineteen clinical studies were included in the network meta-analysis. Compared with no prophylaxis, apixaban reduced CRT incidence (OR 0.31, 95% CI 0.17–0.54), and vitamin K antagonists (VKA), rivaroxaban, and LMWH also showed significant reductions. VKA was associated with a higher bleeding risk than apixaban (OR 2.29, 95% CI 1.08–4.98) and no prophylaxis. No significant differences were found for major bleeding, all-cause mortality, or adverse events among other treatments.ConclusionApixaban, VKA, rivaroxaban, and LMWH effectively prevent CRT, while VKA is associated with an increased bleeding risk. These findings support the favorable effect of DOACs on CRT prevention. Long-term safety data from large-scale, multicenter trials are still needed.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD420251218825.
